amlodipine has been researched along with Connective Tissue Diseases in 1 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Connective Tissue Diseases: A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, EY | 1 |
| Park, JK | 1 |
| Lee, W | 1 |
| Kim, YK | 1 |
| Park, CS | 1 |
| Giles, JT | 1 |
| Park, JW | 1 |
| Shin, K | 1 |
| Lee, JS | 1 |
| Song, YW | 1 |
| Lee, EB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Phosphodiesterase-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon, Double Blind, Randomized, Cross-over Trial[NCT01280266] | Phase 2/Phase 3 | 29 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
0 - unlimited. Number of digital ulcers in all fingers are counted by the investigators and recorded at each visit. The number of ulcers in all fingers indirectly reflect the extent of critical ischemia. As such. the decrease in digital ulcer number reflects positive response to treatment (=better blood flow), whereas the increase ulcer numbers indicates worsening finger ischemia from baseline. (NCT01280266)
Timeframe: baseline and 4 weeks
| Intervention | Digital ulcers (Mean) |
|---|---|
| Amlodipine | 0.1 |
| Udenafil | 0.1 |
Ordinal scale 0-10 0 good 10 bad (NCT01280266)
Timeframe: 0 and 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Amlodipine | 0.1 |
| Udenafil | -0.1 |
"Change in digital artery flow velocity in proper palmar digital artery in cm/sec.~0-unlimited" (NCT01280266)
Timeframe: baseline and 4 weeks
| Intervention | cm/sec (Mean) |
|---|---|
| Amlodipine | -19.9 |
| Udenafil | 63.2 |
"Physician's global assessment (PGA) on VAS assesses the overall condition of the patient. The scale ranges from 0 - 10, with 0 being good and 10 bad. As such, change in the GPA measures the change in the patient's condition from the baseline.~negative value (decrease in value) means improvement." (NCT01280266)
Timeframe: at 0 (baseline) and 4 weeks (after treatment)
| Intervention | units on a scale (Mean) |
|---|---|
| Amlodipine | -0.9 |
| Udenafil | -1.5 |
"change in the RCS. RCS combines daily activty, frequency, duration and severity as well as impact of RP attack (Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon, Merkel et al,Arthritis Rheum. 2002 Sep;46(9):2410-20).~Range 0-10 ordinal scale 0..good 10.. bad" (NCT01280266)
Timeframe: baseline and 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Amlodipine | -0.5 |
| Udenafil | -0.3 |
Change in the average RP duration in minutes (min) per attack. 0 -- unlimited (NCT01280266)
Timeframe: baseline and 4 weeks
| Intervention | min per attack (Mean) |
|---|---|
| Amlodipine | -1.1 |
| Udenafil | -1.4 |
The temperature difference between finger tips and dorsum of same hand. range 0 - unlimited in degree celcius. (NCT01280266)
Timeframe: baseline and 4 weeks
| Intervention | degree celcius. (Mean) |
|---|---|
| Amlodipine | -0.7 |
| Udenafil | -1.4 |
Change in RP frequency after amlodipine and udenafil number of RP attack per day 0 -- unlimited. (NCT01280266)
Timeframe: baselin and 4 weeks
| Intervention | attacks per day (Mean) |
|---|---|
| Amlodipine | -0.5 |
| Udenafil | -0.5 |
changes in the averaged blood flow (Time-averaged peak velocity) Blood flow in cm/sec 0 - unlimited. (NCT01280266)
Timeframe: baseline and 4 weeks
| Intervention | cm/sec (Mean) |
|---|---|
| Amlodipine | -17.3 |
| Udenafil | 33.4 |
1 trial available for amlodipine and Connective Tissue Diseases
| Article | Year |
|---|---|
Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: a double-blind, randomized, cross-over study.
Topics: Adult; Amlodipine; Connective Tissue Diseases; Cross-Over Studies; Double-Blind Method; Female; Fing | 2014 |